Interventional Oncology Market Report 2026

The interventional oncology market size has grown strongly in recent years. It will grow from $2.72 billion in 2025 to $2.96 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rising global cancer incidence rates, expansion of interventional radiology services, growing preference for minimally invasive procedures, improved availability of imaging-guided devices, increased hospital oncology investments.

The interventional oncology market size is expected to see strong growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing adoption of AI-assisted imaging guidance, rising demand for outpatient cancer treatments, expansion of personalized oncology approaches, growing investments in advanced ablation technologies, increasing focus on reduced patient recovery times. Major trends in the forecast period include increasing adoption of image-guided cancer therapies, rising use of minimally invasive ablation procedures, growing integration of advanced imaging modalities, expansion of targeted tumor treatment techniques, enhanced focus on precision oncology.

The increasing prevalence of cancer is expected to drive the growth of the interventional oncology market in the coming years. Cancer prevalence refers to the total number of people, both newly diagnosed and previously diagnosed, who are living with a history of cancer at a given time. This prevalence is rising due to lifestyle-related risk factors, including poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, which increase the likelihood of developing various cancers. Interventional oncology supports cancer treatment by providing minimally invasive, targeted therapies that focus directly on tumors. These approaches improve patient outcomes by reducing damage to healthy tissue and offering faster recovery times compared to traditional treatments. For example, in February 2024, the World Health Organization reported that over 35 million new cancer cases are projected by 2050, representing a 77% increase from the estimated 20 million cases in 2022. This trend is driving the expansion of the interventional oncology market.

Leading companies in the interventional oncology market are developing advanced products, such as microcatheter-based embolization systems, to deliver precise, targeted cancer therapy while minimizing harm to surrounding healthy tissue. Microcatheter-based embolization systems are medical devices that use small, flexible catheters to deliver embolic agents directly into blood vessels, blocking or reducing blood flow for the treatment of tumors, vascular malformations, or bleeding. For instance, in March 2025, Terumo Corporation, a Japan-based medical device company, launched the Occlusafe balloon occlusion catheter, part of its advanced Balloon-TACE (B-TACE) therapy for liver cancer, particularly hepatocellular carcinoma (HCC). This microcatheter leverages pressure gradients to redirect blood flow and access the microcirculation, enabling higher concentrations of therapeutic agents at the tumor site while minimizing off-target embolization. This targeted method aims to improve outcomes in challenging liver cancer cases by enhancing drug delivery precision and providing improved procedural visualization.

In June 2025, Boston Scientific Corporation, a US-based healthcare technology company, acquired Intera Oncology Inc. for an undisclosed sum. This acquisition aims to expand Boston Scientific’s interventional oncology portfolio and strengthen its liver-directed therapy offerings by integrating Intera’s hepatic artery infusion capabilities into its Peripheral Interventions division. Intera Oncology Inc., based in the US, specializes in hepatic artery infusion therapy and commercializes the FDA-approved Intera 3000 Hepatic Artery Infusion Pump along with floxuridine chemotherapy for treating liver-dominant metastases.

Major companies operating in the interventional oncology market are Johnson & Johnson, Siemens Healthineers AG, Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Terumo Corporation, Hologic Inc., Teleflex Incorporated, Lantheus Holdings Inc., Penumbra Inc., Merit Medical Systems Inc., Guerbet SA, Asahi Intecc Co. Ltd., AngioDynamics Inc., Sirtex Medical Limited, Delcath Systems Inc., ABK Biomedical Inc., Profound Medical Inc., IceCure Medical Ltd., Medtronic plc, Koninklijke Philips NV, Cook Medical Incorporated.

North America was the largest region in the interventional oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the interventional oncology market by increasing costs of imported imaging systems, ablation devices, embolization materials, precision catheters, and advanced electronic components. Hospitals and cancer centers in North America and Europe are most affected due to reliance on imported high-end medical devices, while Asia-Pacific faces higher equipment procurement costs. These tariffs are increasing procedural costs and delaying technology upgrades. However, they are also encouraging local device manufacturing, regional supplier partnerships, and innovation in cost-efficient interventional oncology solutions.

The interventional oncology market research report is one of a series of new reports that provides interventional oncology market statistics, including interventional oncology industry global market size, regional shares, competitors with a interventional oncology market share, detailed interventional oncology market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology industry. This interventional oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interventional oncology is a medical specialty that focuses on minimally invasive, image-guided procedures to diagnose and treat cancer. Its primary goal is to provide effective cancer therapies with shorter recovery times and fewer side effects compared to traditional surgical approaches.

The main categories of interventional oncology include radiation therapy devices, ablation devices, and embolization devices. Radiation therapy devices are specialized medical equipment designed to deliver precise doses of ionizing radiation to targeted areas, treating cancer and other diseases by destroying or damaging abnormal cells while minimizing damage to surrounding healthy tissue. These devices use technologies such as ultrasound, computed tomography (CT) guidance, and magnetic resonance imaging (MRI) guidance. Procedures performed with these devices include tumor ablation, tumor biopsy, vascular interventions, and palliative care. Interventional oncology treatments are applied to a range of cancers, including liver, lung, kidney, pancreatic, and prostate cancers, and serve diverse end users such as hospitals, ambulatory surgical centers, specialty clinics, and research and academic institutions.

The interventional oncology market consists of revenues earned by entities by providing services such as image-guided tumor ablation, biopsy and diagnostic imaging, pain palliation procedures, and thermal ablation planning and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional oncology market also includes sales of image-guided navigation systems, catheters and guidewires, radiation delivery systems, and biopsy needles and systems. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.